On Jan. 23, 2015, Novartis announced the US Food and Drug Administration (FDA) had granted accelerated approval of Bexsero (Meningococcal Group B Vaccine [recombinant, adsorbed]) for active immunization to prevent invasive meningococcal disease caused by serogroup B (also known as meningitis B) in adolescents and young adults from 10 years through 25 years of age.

Bexsero was the only meningitis B vaccine approved in the U.S. with a two-dose regimen and a flexible dosing schedule.